We are live on ! Find out more
TGTX icon

TG Therapeutics
TGTX

67 hedge funds and large institutions have $122M invested in TG Therapeutics in 2014 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 2

680% more call options, than puts

Call options by funds: $7.49M | Put options by funds: $960K

52% more capital invested

Capital invested by funds: $80.2M → $122M (+$41.7M)

32% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 19

31% more funds holding

Funds holding: 51 → 67 (+16)

Holders
67
Holders Change
+16
Holders Change %
+31.37%
% of All Funds
1.93%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
25
Reduced
19
Closed
2
Calls
$7.49M
Puts
$960K
Net Calls
+$6.53M
Net Calls Change
+$5.01M

Top Buyers

Rank Fund Capital Flow
1
VAM
Visium Asset Management
New York
+$4.03M
2
Millennium Management
Millennium Management
New York
+$1.73M
3
TC
TFS Capital
Pennsylvania
+$1.07M
4
CCI
Columbus Circle Investors
+$1.02M
5
Invesco
Invesco
Georgia
+$899K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$3.52M
2
SFM
Sphera Funds Management
Israel
-$895K
3
SGAM
Smith Group Asset Management
Texas
-$721K
4
Morgan Stanley
Morgan Stanley
New York
-$592K
5
Jennison Associates
Jennison Associates
New York
-$307K
Name Holding Trade Value Shares
Change 		Change in
Stake
BM
1
Bridger Management
New York
$23.9M – – –
JP Morgan Chase
2
JP Morgan Chase
New York
$21.4M -$3.52M -551,260 -20%
BBA
3
Baker Bros. Advisors
New York
$20.3M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$7.22M +$230K +36,048 +5%
VAM
5
Visium Asset Management
New York
$5.92M +$4.03M +630,380 New
BFA
6
BlackRock Fund Advisors
California
$5.32M +$690K +107,926 +24%
CCI
7
Columbus Circle Investors
$3.84M +$1.02M +159,717 +64%
Jennison Associates
8
Jennison Associates
New York
$3.84M -$307K -48,009 -11%
TC
9
TFS Capital
Pennsylvania
$3.26M +$1.07M +167,701 +94%
Millennium Management
10
Millennium Management
New York
$2.54M +$1.73M +270,722 New
BIT
11
BlackRock Institutional Trust
California
$2.29M +$490K +76,612 +46%
Northern Trust
12
Northern Trust
Illinois
$2.1M +$31.1K +4,864 +2%
State Street
13
State Street
Massachusetts
$2.09M +$87.3K +13,656 +7%
Invesco
14
Invesco
Georgia
$1.71M +$899K +140,542 +343%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$1.64M +$143K +22,340 +15%
EI
16
EAM Investors
California
$1.28M +$872K +136,392 New
EAM
17
Eventide Asset Management
Massachusetts
$1.27M +$863K +135,000 New
Bank of New York Mellon
18
Bank of New York Mellon
New York
$1.13M +$197K +30,839 +34%
Jane Street
19
Jane Street
New York
$946K +$644K +100,759 New
TCIM
20
TIAA CREF Investment Management
New York
$918K +$137K +21,475 +28%
SGAM
21
Smith Group Asset Management
Texas
$770K -$721K -112,712 -58%
California Public Employees Retirement System
22
California Public Employees Retirement System
California
$726K +$256K +40,100 +108%
BIM
23
BlackRock Investment Management
Delaware
$636K +$119K +18,635 +38%
SIP
24
Stoneridge Investment Partners
Pennsylvania
$632K -$13.1K -2,050 -3%
SFM
25
Sphera Funds Management
Israel
$563K -$895K -140,000 -70%
1
2 3

TGTX Hedge Fund Activity: Q2 2014 in Review

67 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q2 2014, worth a combined $122M — up 52% from $80.2M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new TGTX positions and 2 closed out — a net gain of 16 holders — while 25 added to existing stakes and 19 trimmed.

The largest buyer was Visium Asset Management, opening a new position worth an estimated $4.03M. The largest seller was JP Morgan Chase, cutting an estimated $3.52M.

  • 67 institutional investors held TG Therapeutics (TGTX) as of Q2 2014, up from 51 in Q1 2014.
  • Funds reported $122M of TG Therapeutics stock for Q2 2014, up 52% quarter-over-quarter.
  • 18 funds opened new TG Therapeutics positions in Q2 2014 and 2 closed out, a net change of +16 holders.
  • The largest TG Therapeutics buyer in Q2 2014 was Visium Asset Management, an estimated $4.03M added.
  • The largest TG Therapeutics seller in Q2 2014 was JP Morgan Chase, an estimated $3.52M sold.

Based on aggregated 13F filings for Q2 2014.